glp 1 receptor agonist GLP-1 agonists and next-generation metabolic hormone therapies in chronic kidney disease Frontiers | GLP-1 Receptor Agonists:

Description

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

Almost three decades ago, the discovery of leptin triggered a new era of molecular obesity research

If more than 72 hours have passed, skip the dose and take the next one on a regularly scheduled day

And weight gain is a common result for some patients who halt their use of these medications

1 Figure 1 shows the numerous physiological effects of GLP-1 agonists, affecting a wide range of systems including the brain, muscle, pancreas, liver and heart